Anti-Mouse CD18 (Clone C71/16) – Purified in vivo PLATINUM™ Functional Grade

Commonly used antibodies or proteins studied alongside C71/16 (anti-CD18, integrin β2) in the literature typically include those that recognize the α-chains (CD11a, CD11b, CD11c), as well as markers for immune cell identification and functional assays. This is because CD18 is the shared β-subunit that pairs with various α-integrins to form important leukocyte adhesion molecules.

Key antibodies or proteins commonly used with C71/16 include:

• Anti-CD11a (LFA-1, αL integrin): Forms the LFA-1 complex with CD18. Frequently used to assess the αLβ2 integrin function in leukocyte adhesion and migration.
• Anti-CD11b (Mac-1, αM integrin): Forms Mac-1 (αMβ2) with CD18, playing a role in phagocytosis, cell migration, and inflammation.
• Anti-CD11c (αX integrin): Forms p150,95 (αXβ2), particularly important in dendritic cell studies.
• Immune cell subset markers: Antibodies against CD3 (T cells), CD19 (B cells), CD45 (pan-leukocyte), and other lineage-specific markers are typically included in multicolor flow cytometry panels to define which cells express integrins.
• Fc block reagents: Such as anti-CD16/CD32 (FcγRII/III), are commonly used in protocols to reduce non-specific binding before staining for CD18 and related markers.

Relevant published panels often use:

• Fluorescently conjugated anti-CD18 (such as C71/16-FITC), anti-CD11a-PE, anti-CD11b-APC, and markers for T cells or myeloid cells for detailed leukocyte profiling by flow cytometry.

Summary table:

The combination of C71/16 with CD11a, CD11b, CD11c, and cell lineage markers is extensively reported in studies examining immune integrin biology, cell adhesion, and leukocyte function.

If a more targeted list of published panels or specific combinations is required, referencing literature in immunology, particularly in flow cytometry or functional adhesion assays, will yield representative examples where these antibodies are used together.

The clone C71/16 is referenced in relation to Rat anti-CD18 PE antibodies, which are typically used in research involving the study of integrins and their role in cell adhesion and immune responses. The main scientific literature mentioning this clone would likely focus on its application in experiments related to CD18, an important component of the integrin family, particularly in the context of immune cell interactions and inflammation.

While specific key findings directly from clone C71/16 citations are not detailed in the provided search results, the study of CD18 and its related antibodies often pertains to understanding its role in:

• Immune Cell Function: CD18 is crucial for the functioning of various immune cells, including neutrophils and macrophages, impacting their adhesion and migration.
• Inflammation: Alterations in CD18 expression or function can affect inflammatory responses, influencing conditions like autoimmunity and inflammation-related diseases.
• Experimental Models: The use of antibodies like Rat anti-CD18 PE (clone C71/16) helps in characterizing and analyzing immune cell behaviors in experimental setups.

For detailed insights into specific findings related to clone C71/16, reviewing articles that utilize this antibody for research purposes would be necessary.

Dosing regimens for clone C71/16 can vary considerably depending on the specific mouse model and experimental objectives, but there is currently no publicly available data in the provided search results that indicates preferred or standard regimens for this particular antibody clone in mice.

• Most search results, including comprehensive dosing guides for common antibody clones, do not mention C71/16 or its recommended doses across mouse models.
• Other referenced sources relate broadly to dosing of small molecules or other biological agents in mice, but none cite C71/16 by name.

For other clones, typical regimens in mice (for immunotherapy or depletion studies) tend to fall in the range of 100–250 μg per mouse per dose, administered intraperitoneally every 2–3 days or 2–3 times per week. These schedules are optimized according to antibody target, mouse strain, disease model, and experimental endpoints.

If C71/16 is a novel or less commonly used clone, researchers usually:

• Refer to manufacturer or literature-based pilot doses.
• Adjust regimens based on pharmacodynamics (e.g., biomarker response) or toxicity.

Key factors affecting dosing in different mouse models:

• Strain differences (e.g., immunodeficient vs. immunocompetent)
• Disease model (tumor, autoimmune, infection, depletion studies)
• Age and weight of mice
• Route of administration (typically intraperitoneal for antibodies)

Summary: The optimal dosing regimen for clone C71/16 across mouse models is not documented in the provided search results. In the absence of direct literature, researchers should use dosing analogies from similar antibody studies (100–250 μg per mouse, IP, 2–3x/week), and titrate according to specific experimental requirements, referencing primary data where available.

If you need specifics for C71/16, I recommend consulting proprietary datasheets, contacting the manufacturer, or searching primary research publications for direct regimens.

There is no direct information in the current search results regarding dosing regimens of clone C71/16 across different mouse models. None of the available sources explicitly mention clone C71/16, its use, or its dosage in any specific mouse model.

However, you may find that dosing regimens for therapeutic antibodies in mouse models generally depend on:

• The antibody's target and mechanism of action.
• The disease model employed (e.g., autoimmune, cancer, infection).
• The mouse strain and physiological considerations (e.g., immunodeficient vs. immunocompetent).

Typical dosing schedules for research-grade antibodies (seen in unrelated but instructive examples from source ) are:

• Intraperitoneal (i.p.) routes, 100–500 µg per mouse, given every 3–4 days or 2–3 times per week.
• Dose adjustments are often made based on efficacy, toxicity, and pharmacokinetic properties of the specific clone.

If clone C71/16 is a research antibody, recommended regimens will usually be found in product datasheets, peer-reviewed publications, or antibody dosing guides specific to its target. If you can provide the target or context for C71/16 (e.g., antigen specificity or disease indication), a more tailored answer may be possible.

Given the lack of model-specific data for C71/16 in the current results, consult primary literature or the product supplier for validated regimens. If you need protocol development for a specific mouse model and antibody, general approaches from antibody dosing literature indicate starting within the 100–500 µg/mouse range, adjusted for your study's requirements.